Trial of Colistin Versus Meropenem in Ventilator-associated Pneumonia (VAP) (CR-GNB)
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
1. To demonstrate that colistin iv. is not inferior to meropenem in empiric treatment of
VAP regarding the final point of primary efficacy: mortality in the 28 subsequent days
and clinical healing in patients clinically evaluated.
2. To compare the safety of treatment with colistin vs meropenem in VAP.
3. To compare microbiological efficacy of treatment with colistin vs meropenem in VAP
Phase:
Phase 3
Details
Lead Sponsor:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla